Rotarix OK for use again

The FDA revised its recommendations on rotavirus vaccines last week, rescinding an earlier recommendation that the Rotarix vaccine be avoided.

The warning against Rotarix was issued as a precaution when DNA from porcine circovirus type 1 (PCV1) was found in the vaccine. After evaluation of laboratory results, a review of the scientific literature and input from experts, the FDA has determined that clinicians and health care professionals should resume the use of Rotarix and continue the use of RotaTeq. The benefits of the vaccines outweigh the theoretical risk of PCV1, according to the new FDA alert.